Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study

Skinner, S Rachel, PhD ; Szarewski, Anne, PhD ; Romanowski, Barbara, Prof ; Garland, Suzanne M, Prof ; Lazcano-Ponce, Eduardo, Prof ; Salmerón, Jorge, Prof ; Del Rosario-Raymundo, M Rowena, MD ; Verheijen, René H M, Prof ; Quek, Swee Chong, MBBCh ; da Silva, Daniel P, MD ; Kitchener, Henry, Prof ; Fong, Kah Leng, MRCOG ; Bouchard, Céline, FRCSC ; Money, Deborah M, Prof ; Ilancheran, Arunachalam, MD ; Cruickshank, Margaret E, Prof ; Levin, Myron J, Prof ; Chatterjee, Archana, Prof ; Stapleton, Jack T, Prof ; Martens, Mark, MD ; Quint, Wim, PhD ; David, Marie-Pierre, MSc ; Meric, Dorothée, MSc ; Hardt, Karin, PhD ; Descamps, Dominique, MD ; Geeraerts, Brecht, PhD ; Struyf, Frank, MD ; Dubin, Gary, MD

The Lancet (British edition), 2014-12, Vol.384 (9961), p.2213-2227 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível